Oncolytics Biotech® Announces Publication of REOLYSIN® Abstract for the ASCO 2018 Annual Meeting
May 16, 2018 17:00 ET
|
Oncolytics Biotech, Inc.
CALGARY, Alberta and SAN DIEGO, May 16, 2018 (GLOBE NEWSWIRE) -- Oncolytics Biotech® Inc. (TSX:ONC) (OTCQX:ONCYF), currently developing REOLYSIN® (pelareorep), an intravenously delivered...
Oncolytics Biotech® Reports 2018 First Quarter Results
May 11, 2018 07:00 ET
|
Oncolytics Biotech, Inc.
CALGARY, Alberta and SAN DIEGO, May 11, 2018 (GLOBE NEWSWIRE) -- Oncolytics Biotech® Inc. (TSX:ONC) (OTCQX:ONCYF), currently developing REOLYSIN® (pelareorep), an intravenously delivered...
Oncolytics Biotech® Receives Special Protocol Assessment Agreement from FDA for Phase 3 Clinical Trial of Pelareorep In Metastatic Breast Cancer
May 10, 2018 07:00 ET
|
Oncolytics Biotech, Inc.
CALGARY, Alberta and SAN DIEGO, May 10, 2018 (GLOBE NEWSWIRE) -- Oncolytics Biotech® Inc. (TSX:ONC) (OTCQX:ONCYF), currently developing REOLYSIN® (pelareorep), an intravenously delivered...
Oncolytics Biotech® Announces Voting Results from its Annual General Meeting of Shareholders
May 04, 2018 16:00 ET
|
Oncolytics Biotech, Inc.
CALGARY, Alberta and SAN DIEGO, May 04, 2018 (GLOBE NEWSWIRE) -- Oncolytics Biotech® Inc. (TSX:ONC) (OTCQX:ONCYF), currently developing REOLYSIN® (pelareorep), an intravenously delivered...